Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ProMIS Neurosciences Inc PMN

Healthcare Biotechnology
ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational... see more

Recent & Breaking News (NDAQ:PMN)

ProMIS (T.PMN) webinar explains lucrative opportunity behind novel Alzheimer’s treatment

Stockhouse Editorial July 21, 2016

ProMIS Neurosciences Announces Appointment of Dr. Johanne Kaplan as Chief Development Officer

Canada NewsWire July 21, 2016

ProMIS Neurosciences announces new program to identify novel ALS disease targets on toxic strains of protein TDP43

Canada NewsWire July 19, 2016

ProMIS (T.PMN) CEO to discuss progress toward potential answer to Alzheimer’s

Stockhouse Editorial July 18, 2016

ProMIS Neurosciences Announces Retention of Mackie Research Capital Corporation as Market Maintenance Service Provider

Canada NewsWire July 15, 2016

ProMIS (T.PMN) launches program to identify Alzheimer’s targets on tau protein

Stockhouse Editorial July 14, 2016

ProMIS Neurosciences announces new program to identify novel Alzheimer's disease targets on toxic strains of protein tau

Canada NewsWire July 14, 2016

ProMIS Neurosciences Provides Executive Chairman's Summary from Annual Meeting of Shareholders

Canada NewsWire July 12, 2016

ProMIS Neurosciences Announces Results of Annual Meeting of Shareholders

Canada NewsWire July 5, 2016

ProMIS Neurosciences Announces Two Presentations at the 2016 Alzheimer's Association International Conference

Canada NewsWire June 29, 2016

ProMIS Neurosciences (T.PMN) lists $1.0 million PP in Stockhouse’s new Deal Room

Stockhouse Editorial June 28, 2016

ProMIS Neurosciences announces private placement

Canada NewsWire June 27, 2016

ProMIS (T.PMN) white paper affirms Aβ and Tau prions as Alzheimer’s root cause

Stockhouse Editorial June 23, 2016

ProMIS (T.PMN) CEO explains validation process for breakthrough Alzheimer’s therapy

Stockhouse Editorial June 22, 2016

ProMIS (T.PMN) identifies 5th novel therapeutic target for Alzheimer’s

Stockhouse Editorial June 21, 2016

ProMIS Neurosciences identifies and files provisional patent application for a fifth novel therapeutic target for Alzheimer's disease (AD)

Canada NewsWire June 21, 2016

Building the perfect gun against Alzheimer’s deadly advance

Gaalen Engen June 13, 2016

ProMIS (T.PMN) identifies multiple product candidates for Alzheimer’s treatment

Stockhouse Editorial June 2, 2016

ProMIS Neurosciences announces identification of multiple product candidates targeting Alzheimer's disease

Canada NewsWire June 2, 2016

ProMIS Neurosciences (T.PMN) developing game-changing Alzheimer’s treatment

Gaalen Engen May 31, 2016